INT230-6

Business news, market intelligence, and global industry analysis.

The Latest

Is DLL3 becoming the most strategic biomarker target in neuroendocrine oncology?

realme Buds T310 in Agile White: top true wireless earbuds under ₹2,000

realme Buds T310 review: Are these the best budget ANC earbuds under ₹2,000?

Why support-platform strategy may become a differentiator in schizophrenia treatment markets

Representative image of gold bars and tanker traffic in the Strait of Hormuz, illustrating why gold prices climbed to a one-month high even as the waterway was declared completely open.

What gold’s latest rally says about geopolitical hedging after the Strait of Hormuz reopening

Breakthrough results: Intensity Therapeutics’ INT230-6 delivers strong survival and immune response in phase 1/2 cancer trial

Find out how Intensity Therapeutics’ INT230-6 achieved 11.9-month survival and immune activation in metastatic cancer—read what this means for biotech investors.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

October 30, 2025